The verdict
Our read at a glance.
Whether an unapproved anxiolytic with a documented withdrawal syndrome is a reasonable thing to take for social anxiety or sleep.
- The signal
- Phenibut has a real pharmacological history: it was developed in the Soviet Union, used clinically there, and its GABA-B activity is well characterised. There is no modern approval in the United States, European Union or United Kingdom and no contemporary controlled efficacy programme. The literature that has accumulated in the West is overwhelmingly clinical toxicology - case reports and reviews of dependence, tolerance, withdrawal requiring medical management, and intoxication presenting to emergency departments, alongside analytical work on products sold online.
- The unknown
- Nothing pharmacologically. The uncertainty is entirely about how much is being consumed and by whom, since it is bought as an unregulated powder with no dose standardisation.
- Our read
- The problem is not that it does not work; it is that it works the way a benzodiazepine works, including the part that comes later. A substance whose recreational and supplement literature consists mainly of withdrawal case reports is being sold as a wellness powder with no dosing standard at all.
The mechanism
How it works.
Phenibut is GABA with a phenyl ring added, a modification that lets it cross the blood-brain barrier, which GABA itself cannot do. In the brain it acts principally as an agonist at GABA-B receptors - the same receptor baclofen targets - producing anxiolysis and, at higher doses, sedation. It also has activity at the alpha-2-delta subunit of voltage-gated calcium channels, the target of gabapentin and pregabalin, which contributes to the anxiolytic effect. The dependence follows directly from sustained GABA-B agonism: the system downregulates in response to constant stimulation, so tolerance builds within weeks, and removing the drug leaves an under-inhibited nervous system. That rebound is why withdrawal presents with anxiety, insomnia, autonomic instability, psychosis and seizures, and why it is managed clinically much like withdrawal from a benzodiazepine.
Safety & regulatory boundary
The consequential part.
Not an approved medicine in the United States, and FDA has stated it does not meet the definition of a dietary ingredient - so products marketed as supplements containing it are unlawful. Australia has scheduled it as a prohibited substance and several other jurisdictions have restricted it. Tolerance develops quickly, and withdrawal after regular use resembles benzodiazepine or alcohol withdrawal, including anxiety, insomnia, psychosis and seizures, and has required inpatient management in published cases. Combining it with alcohol or other central depressants is the pattern that produces respiratory depression.
What's next
What we're watching.
Regulatory action on online sales, and continued case surveillance of withdrawal presentations.
Context
Why this is discussed.
It genuinely reduces anxiety and is described as producing sociability without sedation, and it is easy to buy as a powder marketed for relaxation and focus.
The evidence base
12 cited references.
Indexed literature (PubMed)12
Gurley BJ et al. · Basic Clin Pharmacol Toxicol · 2024
Penzak SR et al. · J Clin Pharmacol · 2024
Stewart C et al. · Cureus · 2024
Jouney EA · Curr Psychiatry Rep · 2019
Weleff J et al. · J Addict Med · 2023
Feldman R et al. · Clin Toxicol (Phila) · 2023
Sankary S et al. · Am J Emerg Med · 2017
Lapin I · CNS Drug Rev · 2001
Hardman MI et al. · Bosn J Basic Med Sci · 2019
Cohen PA et al. · Clin Toxicol (Phila) · 2022
Pena F et al. · Pediatr Neonatol · 2022
Sethi R et al. · Prim Care Companion CNS Disord · 2021
Keep reading